The Health Resources and Services Administration today launched a new website that organizations participating in the 340B Drug Pricing Program can use to determine the maximum prices drug companies can charge them for medications sold under the program.

鈥淭he AHA is pleased that, in response to our successful lawsuit, HRSA today launched a new website to shine needed light on 340B drug pricing, which the government has found lacking,鈥 said AHA Executive Vice President Tom Nickels. 鈥淭his website will help make sure hospitals participating in the program are not being overcharged by drug companies and that instances of price gouging can be uncovered and penalties enforced. As prescription drug prices continue to skyrocket, the 340B program is as crucial as ever in helping hospitals provide access to health care services for patients in vulnerable communities.鈥

HRSA last November issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B program. The AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems last September filed a lawsuit to force implementation of the rule. 
 

Related News Articles

Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the鈥
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services鈥 decision to鈥
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug鈥
Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'鈥
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state鈥檚 340B contract pharmacy law prohibiting鈥
Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state鈥檚 340B contract鈥